Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Postoperative Nausea Vomiting Market

ID: MRFR/HC/41643-HCR
200 Pages
Rahul Gotadki
Last Updated: April 15, 2026

Postoperative Nausea and Vomiting Market Research Report: Size, Share, Trend Analysis By Types of Treatment (Pharmacological Treatment, Non-Pharmacological Treatment, Combination Therapy), By Medication Class (5-HT3 Antagonists, Dopamine Antagonists, Antihistamines, Corticosteroids), By Administration Route (Oral, Intravenous, Rectal), By Patient Demographics (Pediatric Patients, Adult Patients, Geriatric Patients) and By Region (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Postoperative Nausea Vomiting Market Infographic
Purchase Options
  1. SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
    1. 1.1 EXECUTIVE SUMMARY | |
      1. 1.1.1 Market Overview | |
      2. 1.1.2 Key Findings | |
      3. 1.1.3 Market Segmentation | |
      4. 1.1.4 Competitive Landscape | |
      5. 1.1.5 Challenges and Opportunities | |
      6. 1.1.6 Future Outlook 2
  2. SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
    1. 2.1 MARKET INTRODUCTION | |
      1. 2.1.1 Definition | |
      2. 2.1.2 Scope of the study | | |
        1. 2.1.2.1 Research Objective | | |
        2. 2.1.2.2 Assumption | | |
        3. 2.1.2.3 Limitations |
    2. 2.2 RESEARCH METHODOLOGY | |
      1. 2.2.1 Overview | |
      2. 2.2.2 Data Mining | |
      3. 2.2.3 Secondary Research | |
      4. 2.2.4 Primary Research | | |
        1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
        2. 2.2.4.2 Breakdown of Primary Respondents | |
      5. 2.2.5 Forecasting Model | |
      6. 2.2.6 Market Size Estimation | | |
        1. 2.2.6.1 Bottom-Up Approach | | |
        2. 2.2.6.2 Top-Down Approach | |
      7. 2.2.7 Data Triangulation | |
      8. 2.2.8 Validation 3
  3. SECTION III: QUALITATIVE ANALYSIS |
    1. 3.1 MARKET DYNAMICS | |
      1. 3.1.1 Overview | |
      2. 3.1.2 Drivers | |
      3. 3.1.3 Restraints | |
      4. 3.1.4 Opportunities |
    2. 3.2 MARKET FACTOR ANALYSIS | |
      1. 3.2.1 Value chain Analysis | |
      2. 3.2.2 Porter's Five Forces Analysis | | |
        1. 3.2.2.1 Bargaining Power of Suppliers | | |
        2. 3.2.2.2 Bargaining Power of Buyers | | |
        3. 3.2.2.3 Threat of New Entrants | | |
        4. 3.2.2.4 Threat of Substitutes | | |
        5. 3.2.2.5 Intensity of Rivalry | |
      3. 3.2.3 COVID-19 Impact Analysis | | |
        1. 3.2.3.1 Market Impact Analysis | | |
        2. 3.2.3.2 Regional Impact | | |
        3. 3.2.3.3 Opportunity and Threat Analysis 4
  4. SECTION IV: QUANTITATIVE ANALYSIS |
    1. 4.1 Healthcare, BY Type of Treatment (USD Billion) | |
      1. 4.1.1 Pharmacological Treatment | |
      2. 4.1.2 Non-Pharmacological Treatment | |
      3. 4.1.3 Combination Therapy |
    2. 4.2 Healthcare, BY Medication Class (USD Billion) | |
      1. 4.2.1 5-HT3 Antagonists | |
      2. 4.2.2 Dopamine Antagonists | |
      3. 4.2.3 Antihistamines | |
      4. 4.2.4 Corticosteroids |
    3. 4.3 Healthcare, BY Administration Route (USD Billion) | |
      1. 4.3.1 Oral | |
      2. 4.3.2 Intravenous | |
      3. 4.3.3 Rectal |
    4. 4.4 Healthcare, BY Patient Demographics (USD Billion) | |
      1. 4.4.1 Pediatric Patients | |
      2. 4.4.2 Adult Patients | |
      3. 4.4.3 Geriatric Patients |
    5. 4.5 Healthcare, BY Region (USD Billion) | |
      1. 4.5.1 North America | | |
        1. 4.5.1.1 US | | |
        2. 4.5.1.2 Canada | |
      2. 4.5.2 Europe | | |
        1. 4.5.2.1 Germany | | |
        2. 4.5.2.2 UK | | |
        3. 4.5.2.3 France | | |
        4. 4.5.2.4 Russia | | |
        5. 4.5.2.5 Italy | | |
        6. 4.5.2.6 Spain | | |
        7. 4.5.2.7 Rest of Europe | |
      3. 4.5.3 APAC | | |
        1. 4.5.3.1 China | | |
        2. 4.5.3.2 India | | |
        3. 4.5.3.3 Japan | | |
        4. 4.5.3.4 South Korea | | |
        5. 4.5.3.5 Malaysia | | |
        6. 4.5.3.6 Thailand | | |
        7. 4.5.3.7 Indonesia | | |
        8. 4.5.3.8 Rest of APAC | |
      4. 4.5.4 South America | | |
        1. 4.5.4.1 Brazil | | |
        2. 4.5.4.2 Mexico | | |
        3. 4.5.4.3 Argentina | | |
        4. 4.5.4.4 Rest of South America | |
      5. 4.5.5 MEA | | |
        1. 4.5.5.1 GCC Countries | | |
        2. 4.5.5.2 South Africa | | |
        3. 4.5.5.3 Rest of MEA 5
  5. SECTION V: COMPETITIVE ANALYSIS |
    1. 5.1 Competitive Landscape | |
      1. 5.1.1 Overview | |
      2. 5.1.2 Competitive Analysis | |
      3. 5.1.3 Market share Analysis | |
      4. 5.1.4 Major Growth Strategy in the Healthcare | |
      5. 5.1.5 Competitive Benchmarking | |
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | |
      7. 5.1.7 Key developments and growth strategies | | |
        1. 5.1.7.1 New Product Launch/Service Deployment | | |
        2. 5.1.7.2 Merger & Acquisitions | | |
        3. 5.1.7.3 Joint Ventures | |
      8. 5.1.8 Major Players Financial Matrix | | |
        1. 5.1.8.1 Sales and Operating Income | | |
        2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
    2. 5.2 Company Profiles | |
      1. 5.2.1 Fresenius Kabi (DE) | | |
        1. 5.2.1.1 Financial Overview | | |
        2. 5.2.1.2 Products Offered | | |
        3. 5.2.1.3 Key Developments | | |
        4. 5.2.1.4 SWOT Analysis | | |
        5. 5.2.1.5 Key Strategies | |
      2. 5.2.2 Baxter International (US) | | |
        1. 5.2.2.1 Financial Overview | | |
        2. 5.2.2.2 Products Offered | | |
        3. 5.2.2.3 Key Developments | | |
        4. 5.2.2.4 SWOT Analysis | | |
        5. 5.2.2.5 Key Strategies | |
      3. 5.2.3 GlaxoSmithKline (GB) | | |
        1. 5.2.3.1 Financial Overview | | |
        2. 5.2.3.2 Products Offered | | |
        3. 5.2.3.3 Key Developments | | |
        4. 5.2.3.4 SWOT Analysis | | |
        5. 5.2.3.5 Key Strategies | |
      4. 5.2.4 Merck & Co. (US) | | |
        1. 5.2.4.1 Financial Overview | | |
        2. 5.2.4.2 Products Offered | | |
        3. 5.2.4.3 Key Developments | | |
        4. 5.2.4.4 SWOT Analysis | | |
        5. 5.2.4.5 Key Strategies | |
      5. 5.2.5 AstraZeneca (GB) | | |
        1. 5.2.5.1 Financial Overview | | |
        2. 5.2.5.2 Products Offered | | |
        3. 5.2.5.3 Key Developments | | |
        4. 5.2.5.4 SWOT Analysis | | |
        5. 5.2.5.5 Key Strategies | |
      6. 5.2.6 Novartis (CH) | | |
        1. 5.2.6.1 Financial Overview | | |
        2. 5.2.6.2 Products Offered | | |
        3. 5.2.6.3 Key Developments | | |
        4. 5.2.6.4 SWOT Analysis | | |
        5. 5.2.6.5 Key Strategies | |
      7. 5.2.7 Teva Pharmaceutical Industries (IL) | | |
        1. 5.2.7.1 Financial Overview | | |
        2. 5.2.7.2 Products Offered | | |
        3. 5.2.7.3 Key Developments | | |
        4. 5.2.7.4 SWOT Analysis | | |
        5. 5.2.7.5 Key Strategies | |
      8. 5.2.8 Eisai Co., Ltd. (JP) | | |
        1. 5.2.8.1 Financial Overview | | |
        2. 5.2.8.2 Products Offered | | |
        3. 5.2.8.3 Key Developments | | |
        4. 5.2.8.4 SWOT Analysis | | |
        5. 5.2.8.5 Key Strategies | |
      9. 5.2.9 Hikma Pharmaceuticals (GB) | | |
        1. 5.2.9.1 Financial Overview | | |
        2. 5.2.9.2 Products Offered | | |
        3. 5.2.9.3 Key Developments | | |
        4. 5.2.9.4 SWOT Analysis | | |
        5. 5.2.9.5 Key Strategies |
    3. 5.3 Appendix | |
      1. 5.3.1 References | |
      2. 5.3.2 Related Reports 6 LIST OF FIGURES |
    4. 6.1 MARKET SYNOPSIS |
    5. 6.2 NORTH AMERICA MARKET ANALYSIS |
    6. 6.3 US MARKET ANALYSIS BY TYPE OF TREATMENT |
    7. 6.4 US MARKET ANALYSIS BY MEDICATION CLASS |
    8. 6.5 US MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    9. 6.6 US MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
    10. 6.7 CANADA MARKET ANALYSIS BY TYPE OF TREATMENT |
    11. 6.8 CANADA MARKET ANALYSIS BY MEDICATION CLASS |
    12. 6.9 CANADA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    13. 6.10 CANADA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
    14. 6.11 EUROPE MARKET ANALYSIS |
    15. 6.12 GERMANY MARKET ANALYSIS BY TYPE OF TREATMENT |
    16. 6.13 GERMANY MARKET ANALYSIS BY MEDICATION CLASS |
    17. 6.14 GERMANY MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    18. 6.15 GERMANY MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
    19. 6.16 UK MARKET ANALYSIS BY TYPE OF TREATMENT |
    20. 6.17 UK MARKET ANALYSIS BY MEDICATION CLASS |
    21. 6.18 UK MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    22. 6.19 UK MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
    23. 6.20 FRANCE MARKET ANALYSIS BY TYPE OF TREATMENT |
    24. 6.21 FRANCE MARKET ANALYSIS BY MEDICATION CLASS |
    25. 6.22 FRANCE MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    26. 6.23 FRANCE MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
    27. 6.24 RUSSIA MARKET ANALYSIS BY TYPE OF TREATMENT |
    28. 6.25 RUSSIA MARKET ANALYSIS BY MEDICATION CLASS |
    29. 6.26 RUSSIA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    30. 6.27 RUSSIA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
    31. 6.28 ITALY MARKET ANALYSIS BY TYPE OF TREATMENT |
    32. 6.29 ITALY MARKET ANALYSIS BY MEDICATION CLASS |
    33. 6.30 ITALY MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    34. 6.31 ITALY MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
    35. 6.32 SPAIN MARKET ANALYSIS BY TYPE OF TREATMENT |
    36. 6.33 SPAIN MARKET ANALYSIS BY MEDICATION CLASS |
    37. 6.34 SPAIN MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    38. 6.35 SPAIN MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
    39. 6.36 REST OF EUROPE MARKET ANALYSIS BY TYPE OF TREATMENT |
    40. 6.37 REST OF EUROPE MARKET ANALYSIS BY MEDICATION CLASS |
    41. 6.38 REST OF EUROPE MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    42. 6.39 REST OF EUROPE MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
    43. 6.40 APAC MARKET ANALYSIS |
    44. 6.41 CHINA MARKET ANALYSIS BY TYPE OF TREATMENT |
    45. 6.42 CHINA MARKET ANALYSIS BY MEDICATION CLASS |
    46. 6.43 CHINA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    47. 6.44 CHINA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
    48. 6.45 INDIA MARKET ANALYSIS BY TYPE OF TREATMENT |
    49. 6.46 INDIA MARKET ANALYSIS BY MEDICATION CLASS |
    50. 6.47 INDIA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    51. 6.48 INDIA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
    52. 6.49 JAPAN MARKET ANALYSIS BY TYPE OF TREATMENT |
    53. 6.50 JAPAN MARKET ANALYSIS BY MEDICATION CLASS |
    54. 6.51 JAPAN MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    55. 6.52 JAPAN MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
    56. 6.53 SOUTH KOREA MARKET ANALYSIS BY TYPE OF TREATMENT |
    57. 6.54 SOUTH KOREA MARKET ANALYSIS BY MEDICATION CLASS |
    58. 6.55 SOUTH KOREA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    59. 6.56 SOUTH KOREA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
    60. 6.57 MALAYSIA MARKET ANALYSIS BY TYPE OF TREATMENT |
    61. 6.58 MALAYSIA MARKET ANALYSIS BY MEDICATION CLASS |
    62. 6.59 MALAYSIA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    63. 6.60 MALAYSIA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
    64. 6.61 THAILAND MARKET ANALYSIS BY TYPE OF TREATMENT |
    65. 6.62 THAILAND MARKET ANALYSIS BY MEDICATION CLASS |
    66. 6.63 THAILAND MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    67. 6.64 THAILAND MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
    68. 6.65 INDONESIA MARKET ANALYSIS BY TYPE OF TREATMENT |
    69. 6.66 INDONESIA MARKET ANALYSIS BY MEDICATION CLASS |
    70. 6.67 INDONESIA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    71. 6.68 INDONESIA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
    72. 6.69 REST OF APAC MARKET ANALYSIS BY TYPE OF TREATMENT |
    73. 6.70 REST OF APAC MARKET ANALYSIS BY MEDICATION CLASS |
    74. 6.71 REST OF APAC MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    75. 6.72 REST OF APAC MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
    76. 6.73 SOUTH AMERICA MARKET ANALYSIS |
    77. 6.74 BRAZIL MARKET ANALYSIS BY TYPE OF TREATMENT |
    78. 6.75 BRAZIL MARKET ANALYSIS BY MEDICATION CLASS |
    79. 6.76 BRAZIL MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    80. 6.77 BRAZIL MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
    81. 6.78 MEXICO MARKET ANALYSIS BY TYPE OF TREATMENT |
    82. 6.79 MEXICO MARKET ANALYSIS BY MEDICATION CLASS |
    83. 6.80 MEXICO MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    84. 6.81 MEXICO MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
    85. 6.82 ARGENTINA MARKET ANALYSIS BY TYPE OF TREATMENT |
    86. 6.83 ARGENTINA MARKET ANALYSIS BY MEDICATION CLASS |
    87. 6.84 ARGENTINA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    88. 6.85 ARGENTINA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
    89. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE OF TREATMENT |
    90. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY MEDICATION CLASS |
    91. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    92. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
    93. 6.90 MEA MARKET ANALYSIS |
    94. 6.91 GCC COUNTRIES MARKET ANALYSIS BY TYPE OF TREATMENT |
    95. 6.92 GCC COUNTRIES MARKET ANALYSIS BY MEDICATION CLASS |
    96. 6.93 GCC COUNTRIES MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    97. 6.94 GCC COUNTRIES MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
    98. 6.95 SOUTH AFRICA MARKET ANALYSIS BY TYPE OF TREATMENT |
    99. 6.96 SOUTH AFRICA MARKET ANALYSIS BY MEDICATION CLASS |
    100. 6.97 SOUTH AFRICA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    101. 6.98 SOUTH AFRICA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
    102. 6.99 REST OF MEA MARKET ANALYSIS BY TYPE OF TREATMENT |
    103. 6.100 REST OF MEA MARKET ANALYSIS BY MEDICATION CLASS |
    104. 6.101 REST OF MEA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    105. 6.102 REST OF MEA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
    106. 6.103 KEY BUYING CRITERIA OF HEALTHCARE |
    107. 6.104 RESEARCH PROCESS OF MRFR |
    108. 6.105 DRO ANALYSIS OF HEALTHCARE |
    109. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE |
    110. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
    111. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE |
    112. 6.109 HEALTHCARE, BY TYPE OF TREATMENT, 2024 (% SHARE) |
    113. 6.110 HEALTHCARE, BY TYPE OF TREATMENT, 2024 TO 2035 (USD Billion) |
    114. 6.111 HEALTHCARE, BY MEDICATION CLASS, 2024 (% SHARE) |
    115. 6.112 HEALTHCARE, BY MEDICATION CLASS, 2024 TO 2035 (USD Billion) |
    116. 6.113 HEALTHCARE, BY ADMINISTRATION ROUTE, 2024 (% SHARE) |
    117. 6.114 HEALTHCARE, BY ADMINISTRATION ROUTE, 2024 TO 2035 (USD Billion) |
    118. 6.115 HEALTHCARE, BY PATIENT DEMOGRAPHICS, 2024 (% SHARE) |
    119. 6.116 HEALTHCARE, BY PATIENT DEMOGRAPHICS, 2024 TO 2035 (USD Billion) |
    120. 6.117 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
    121. 7.1 LIST OF ASSUMPTIONS | |
      1. 7.1.1 |
    122. 7.2 North America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.2.1 BY TYPE OF TREATMENT, 2025-2035 (USD Billion) | |
      2. 7.2.2 BY MEDICATION CLASS, 2025-2035 (USD Billion) | |
      3. 7.2.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      4. 7.2.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) |
    123. 7.3 US MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.3.1 BY TYPE OF TREATMENT, 2025-2035 (USD Billion) | |
      2. 7.3.2 BY MEDICATION CLASS, 2025-2035 (USD Billion) | |
      3. 7.3.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      4. 7.3.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) |
    124. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.4.1 BY TYPE OF TREATMENT, 2025-2035 (USD Billion) | |
      2. 7.4.2 BY MEDICATION CLASS, 2025-2035 (USD Billion) | |
      3. 7.4.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      4. 7.4.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) |
    125. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.5.1 BY TYPE OF TREATMENT, 2025-2035 (USD Billion) | |
      2. 7.5.2 BY MEDICATION CLASS, 2025-2035 (USD Billion) | |
      3. 7.5.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      4. 7.5.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) |
    126. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.6.1 BY TYPE OF TREATMENT, 2025-2035 (USD Billion) | |
      2. 7.6.2 BY MEDICATION CLASS, 2025-2035 (USD Billion) | |
      3. 7.6.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      4. 7.6.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) |
    127. 7.7 UK MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.7.1 BY TYPE OF TREATMENT, 2025-2035 (USD Billion) | |
      2. 7.7.2 BY MEDICATION CLASS, 2025-2035 (USD Billion) | |
      3. 7.7.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      4. 7.7.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) |
    128. 7.8 France MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.8.1 BY TYPE OF TREATMENT, 2025-2035 (USD Billion) | |
      2. 7.8.2 BY MEDICATION CLASS, 2025-2035 (USD Billion) | |
      3. 7.8.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      4. 7.8.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) |
    129. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.9.1 BY TYPE OF TREATMENT, 2025-2035 (USD Billion) | |
      2. 7.9.2 BY MEDICATION CLASS, 2025-2035 (USD Billion) | |
      3. 7.9.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      4. 7.9.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) |
    130. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.10.1 BY TYPE OF TREATMENT, 2025-2035 (USD Billion) | |
      2. 7.10.2 BY MEDICATION CLASS, 2025-2035 (USD Billion) | |
      3. 7.10.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      4. 7.10.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) |
    131. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.11.1 BY TYPE OF TREATMENT, 2025-2035 (USD Billion) | |
      2. 7.11.2 BY MEDICATION CLASS, 2025-2035 (USD Billion) | |
      3. 7.11.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      4. 7.11.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) |
    132. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.12.1 BY TYPE OF TREATMENT, 2025-2035 (USD Billion) | |
      2. 7.12.2 BY MEDICATION CLASS, 2025-2035 (USD Billion) | |
      3. 7.12.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      4. 7.12.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) |
    133. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.13.1 BY TYPE OF TREATMENT, 2025-2035 (USD Billion) | |
      2. 7.13.2 BY MEDICATION CLASS, 2025-2035 (USD Billion) | |
      3. 7.13.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      4. 7.13.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) |
    134. 7.14 China MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.14.1 BY TYPE OF TREATMENT, 2025-2035 (USD Billion) | |
      2. 7.14.2 BY MEDICATION CLASS, 2025-2035 (USD Billion) | |
      3. 7.14.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      4. 7.14.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) |
    135. 7.15 India MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.15.1 BY TYPE OF TREATMENT, 2025-2035 (USD Billion) | |
      2. 7.15.2 BY MEDICATION CLASS, 2025-2035 (USD Billion) | |
      3. 7.15.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      4. 7.15.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) |
    136. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.16.1 BY TYPE OF TREATMENT, 2025-2035 (USD Billion) | |
      2. 7.16.2 BY MEDICATION CLASS, 2025-2035 (USD Billion) | |
      3. 7.16.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      4. 7.16.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) |
    137. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.17.1 BY TYPE OF TREATMENT, 2025-2035 (USD Billion) | |
      2. 7.17.2 BY MEDICATION CLASS, 2025-2035 (USD Billion) | |
      3. 7.17.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      4. 7.17.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) |
    138. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.18.1 BY TYPE OF TREATMENT, 2025-2035 (USD Billion) | |
      2. 7.18.2 BY MEDICATION CLASS, 2025-2035 (USD Billion) | |
      3. 7.18.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      4. 7.18.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) |
    139. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.19.1 BY TYPE OF TREATMENT, 2025-2035 (USD Billion) | |
      2. 7.19.2 BY MEDICATION CLASS, 2025-2035 (USD Billion) | |
      3. 7.19.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      4. 7.19.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) |
    140. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.20.1 BY TYPE OF TREATMENT, 2025-2035 (USD Billion) | |
      2. 7.20.2 BY MEDICATION CLASS, 2025-2035 (USD Billion) | |
      3. 7.20.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      4. 7.20.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) |
    141. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.21.1 BY TYPE OF TREATMENT, 2025-2035 (USD Billion) | |
      2. 7.21.2 BY MEDICATION CLASS, 2025-2035 (USD Billion) | |
      3. 7.21.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      4. 7.21.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) |
    142. 7.22 South America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.22.1 BY TYPE OF TREATMENT, 2025-2035 (USD Billion) | |
      2. 7.22.2 BY MEDICATION CLASS, 2025-2035 (USD Billion) | |
      3. 7.22.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      4. 7.22.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) |
    143. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.23.1 BY TYPE OF TREATMENT, 2025-2035 (USD Billion) | |
      2. 7.23.2 BY MEDICATION CLASS, 2025-2035 (USD Billion) | |
      3. 7.23.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      4. 7.23.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) |
    144. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.24.1 BY TYPE OF TREATMENT, 2025-2035 (USD Billion) | |
      2. 7.24.2 BY MEDICATION CLASS, 2025-2035 (USD Billion) | |
      3. 7.24.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      4. 7.24.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) |
    145. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.25.1 BY TYPE OF TREATMENT, 2025-2035 (USD Billion) | |
      2. 7.25.2 BY MEDICATION CLASS, 2025-2035 (USD Billion) | |
      3. 7.25.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      4. 7.25.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) |
    146. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.26.1 BY TYPE OF TREATMENT, 2025-2035 (USD Billion) | |
      2. 7.26.2 BY MEDICATION CLASS, 2025-2035 (USD Billion) | |
      3. 7.26.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      4. 7.26.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) |
    147. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.27.1 BY TYPE OF TREATMENT, 2025-2035 (USD Billion) | |
      2. 7.27.2 BY MEDICATION CLASS, 2025-2035 (USD Billion) | |
      3. 7.27.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      4. 7.27.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) |
    148. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.28.1 BY TYPE OF TREATMENT, 2025-2035 (USD Billion) | |
      2. 7.28.2 BY MEDICATION CLASS, 2025-2035 (USD Billion) | |
      3. 7.28.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      4. 7.28.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) |
    149. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.29.1 BY TYPE OF TREATMENT, 2025-2035 (USD Billion) | |
      2. 7.29.2 BY MEDICATION CLASS, 2025-2035 (USD Billion) | |
      3. 7.29.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      4. 7.29.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) |
    150. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.30.1 BY TYPE OF TREATMENT, 2025-2035 (USD Billion) | |
      2. 7.30.2 BY MEDICATION CLASS, 2025-2035 (USD Billion) | |
      3. 7.30.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      4. 7.30.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) |
    151. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
      1. 7.31.1 |
    152. 7.32 ACQUISITION/PARTNERSHIP | |

Healthcare Market Segmentation

Healthcare By Type of Treatment (USD Billion, 2025-2035)

  • Pharmacological Treatment
  • Non-Pharmacological Treatment
  • Combination Therapy

Healthcare By Medication Class (USD Billion, 2025-2035)

  • 5-HT3 Antagonists
  • Dopamine Antagonists
  • Antihistamines
  • Corticosteroids

Healthcare By Administration Route (USD Billion, 2025-2035)

  • Oral
  • Intravenous
  • Rectal

Healthcare By Patient Demographics (USD Billion, 2025-2035)

  • Pediatric Patients
  • Adult Patients
  • Geriatric Patients

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions